



Ref: FOIA Reference 2023/24-092

Date: 1st June 2023

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 16th May 2023 requesting information under the Freedom of Information Act (2000) regarding ovarian cancer

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I am researching the incidence and treatment of ovarian cancer. We would greatly appreciate if you could answer the following questions.

How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <10 and <20
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Over the time period 01.01.2023 to 31.03.2023 there were <20 treatments at UHNM for patients with FIGO Stages III and IV ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer. <10 of these were first treatments for a new primary cancer and <10 were subsequent treatments (see table below).

	Surgery	Cytotoxic Chemotherapy	Specialist Palliative Care	Grand Total
First Treatment	<5	<5	<5	<10
Subsequent Treatment	<10	<5		<10

Q2 How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- Paclitaxel in combination with a platinum-based compound
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Rucaparib

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Paclitaxel in combination with a platinum-based compound - 24
- Platinum-based therapy alone (cisplatin or carboplatin) - 12
- Bevacizumab in combination with paclitaxel and carboplatin - 11
- Olaparib <5
- Olaparib + Bevacizumab <5
- Niraparib - 10
- Rucaparib - 8

Q3 Does your Trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

Project Short title	Recruited (org)
PRIMA	<5
A Phase 2 study of EP0057 and Olaparib in ovarian cancer patients	0

Q4 If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib

- **Other treatments**

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. Personal information. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Olaparib - 0
- Olaparib + Bevacizumab - <5
- Niraparib - 6
- Other treatments - 0

Q5 If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

A5 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Olaparib - 0
- Olaparib + Bevacizumab - <5
- Niraparib - 0
- Other treatments - 0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Rachel Montinaro
Data Security and Protection Manager - Records